scispace - formally typeset
Open AccessJournal ArticleDOI

Prevalence of age-related macular degeneration in the United States.

TLDR
In this article, the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender was estimated.

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Ranibizumab for Neovascular Age-Related Macular Degeneration

TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI

Complement Factor H Polymorphism in Age-Related Macular Degeneration

TL;DR: A genome-wide screen for polymorphisms associated with age-related macular degeneration revealed a polymorphism in linkage disequilibrium with the risk allele representing a tyrosine-histidine change at amino acid 402 in the complement factor H gene.
Journal ArticleDOI

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Journal ArticleDOI

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

TL;DR: In this article, the authors did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013, using retinal photographs and standardised grading classifications.
References
More filters
Journal ArticleDOI

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

TL;DR: To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with verteporfin (Visudyne) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration (AMD).
Journal ArticleDOI

An international classification and grading system for age-related maculopathy and age-related macular degeneration

TL;DR: A common detection and classification system is needed for epidemiologic studies of age-related maculopathy (ARM) and such a grading scheme for ARM is described in this paper.
Journal ArticleDOI

Prevalence of age-related maculopathy. The Beaver Dam Eye Study.

TL;DR: In this article, the relationship between retinal drusen, retinal pigmentary abnormalities, and macular degeneration to age and sex was studied in 4926 people between the ages of 43 and 86 years who participated in the Beaver Dam Eye Study.
Journal ArticleDOI

Prevalence of Age-related Maculopathy in Australia: The Blue Mountains Eye Study

TL;DR: Detailed prevalence rates for most components of ARM in an Australian population are provided and reinforce the Beaver Dam Eye Study findings for the relative age-specific frequency of age-related macular degeneration components.
Journal ArticleDOI

Age-Specific Prevalence and Causes of Blindness and Visual Impairment in an Older Population: The Rotterdam Study

TL;DR: The hierarchy of causes of blindness and visual impairment is highly determined by age; as yet, little can be done to reduce the exponential increase of blindness; however, adequate implementation of surgery to treat cataract could reduce visual impairment by one third.
Related Papers (5)

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8